Drug Trial Radar · NCT04485195
RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department
Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Actual
Start
Jun 17, 2021
Primary completion
Sep 15, 2024
Study completion Nov 6, 2024
Sponsor
- Lead sponsor
- Ottawa Hospital Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to compare IV vernakalant to IV procainamide for the ED management of acute AF patients. If vernakalant proves to be more effective, faster, and safer than IV procainamide, this will give clinicians an important alternative for pharmacological cardioversion of acute AF. The investigators propose a pragmatic comparative effectiveness trial entailing an open label, randomized controlled trial at 12 large Canadian EDs. Study subjects will be randomized to 1 of 2 treatment arms: 1) Patients will receive an initial infusion of 3mg/kg of IV vernakalant over 10 minutes, followed by a second dose of 2mg/kg over 10 minutes, if necessary, or 2) Patients will receive a continuous infusion of 15mg/kg of IV procainamide over 60 minutes. The primary aim will be to compare conversion to normal sinus rhythm between the two drugs. The investigators will include stable patients presenting with an episode of acute AF of at least 3 hours duration, where symptoms require urgent management and where immediate cardioversion is a reasonable option. Using the integrated consent model, research assistants will obtain verbal consent from eligible patients.
Conditions
- Atrial Fibrillation
Interventions
VernakalantDrug
an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump
ProcainamideDrug
15 mg/kg in 500 mL of normal saline given over 60 minutes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Conversion to sinus rhythm for a minimum duration of 30 minutesTime frame: During any time following randomization until 30 minutes past the completion of the drug infusion
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
University of Alberta Hospital
Edmonton, Alberta, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
St. Paul's Hospital
Vancouver, British Columbia, Canada
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
Hamilton Health Sciences Centre
Hamilton, Ontario, Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
Ottawa Hospital
Ottawa, Ontario, Canada
St. Michaels
Toronto, Ontario, Canada
Sunnybrook Hospital
Toronto, Ontario, Canada
Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval
Laval, Quebec, Canada
Montreal Heart Institute
Montreal, Quebec, Canada
Hopital Du Sacre-Coeur
Montreal, Quebec, Canada
Hopital de L'Enfant-Jesus
Québec, Quebec, Canada
Hôtel-Dieu de Lévis
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.